Gossamer Bio Inc is a biotechnology company focused on discovering and developing innovative medicines to address significant unmet medical needs in various therapeutic areas, including immunology and oncology
The company employs a data-driven approach to identify and advance potential drug candidates through preclinical and clinical stages of development. By leveraging cutting-edge science and technology, Gossamer Bio aims to create targeted treatments that improve patient outcomes and quality of life in complex diseases.
Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Shares of Lantheus Holdings, Inc. (NASDAQLNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.
The Dow Jones closed higher by around 490 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
